Kag, to add further confusion...the 10-K (annual report), which is as official as it gets, states that BOCX has retained the rights to the RIA ("home brew") application but doesn't mention histo-recaf, imaging, etc. Also, in conversations with management I have been told that they retained the rights to the therapy indication.
I'm pretty sure that Abbott licensed serum-RECAF alone.
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.